Gedea´s ambition is to develop the first antibiotic-free treatment that both treats and prevents bacterial vaginosis. pHyph is a vaginal tablet that has shown an excellent medical effect.
pHyph is developed by Gedea Biotech – a company that was set up by a multidisciplinary team from Lund University.
Bacterial vaginosis is a recurring problem that affects women around the world.
CLINICAL TRIALS
In our most recently concluded trial, 90% of patients had a symptom reduction. At day 35 throughout the 4 month follow-up period, recurrence was substantially lower after treatment with pHyph compared to the antibiotic rescue-treated patients.
1. Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.
NEWS
Gedea Biotech reports results from placebo-controlled clinical trial of pHyph, an antibiotic-free treatment for bacterial vaginosis
Gedea Biotech to Start EpHect Clinical Trial for Antibiotic-free Treatment of Women with Vulvo Vaginal Candidiasis
Gedea Biotech wins the "Rapidus company of the year" award
Gedea Biotech has completed the recruitment for NEFERTITI clinical trial of pHyph antibiotic-free treatment of bacterial vaginosis
Gedea Biotech - Top 20 European Biotech Companies to Watch in 2022
Gedea receives funding for microbiome research project with Centre for Translational Microbiome Research at Karolinska Institutet
Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.
